GEP-NET
Clinical trials for GEP-NET explained in plain language.
Never miss a new study
Get alerted when new GEP-NET trials appear
Sign up with your email to follow new studies for GEP-NET, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Radioactive drug takes aim at Hard-to-Treat tumors
Disease control Recruiting nowThis early-phase trial tests a new radioactive drug called RYZ401 in people with neuroendocrine tumors and other solid tumors that have a specific protein on their surface. The drug delivers a powerful radioactive particle directly to cancer cells. The study aims to find the safe…
Matched conditions: GEP-NET
Phase: PHASE1 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New radioactive drug aims to fight gut tumors that resist standard therapy
Disease control Recruiting nowThis study tests a new drug called RYZ101 in people with advanced neuroendocrine tumors (GEP-NETs) that have grown after prior radiation therapy. The trial has two parts: first finding the right dose, then comparing RYZ101 to standard treatments like everolimus or sunitinib. Abou…
Matched conditions: GEP-NET
Phase: PHASE3 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Study aims to personalize treatment for rare gut tumors
Knowledge-focused Recruiting nowThis study looks at how factors like age, sex, tumor grade, and location influence how well treatments work for people with well-differentiated gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Researchers will follow 450 patients to see how long their disease stays und…
Matched conditions: GEP-NET
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC